購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
huRHO-P347S Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huRHO-P347S Mouse
製品名
huRHO-P347S Mouse
製品ID
C002130
系統名
C57BL/6Cya-Rhotm5(hRHO*P347S)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huRHO-P347S Mouse(カタログ番号C002130)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
RP4, OPN2, CSNBAD1
NCBI ID
染色体
Chr 3
MGI ID
さらに
系統詳細
Retinitis pigmentosa (RP) is a hereditary retinal disease with a global prevalence of approximately 1:5000-1:3000. RP is highly clinically and genetically heterogeneous, with mutations in the rhodopsin (RHO) gene causing approximately 25% of dominant RP [1]. The rhodopsin encoded by the RHO gene is closely associated with visual light transduction and GPCR downstream signals. Rhodopsin is essential for the transmission of light signals in the process of vision formation. Most RHO mutations lead to high levels of rhodopsin expression in photoreceptor cells, causing many mutant proteins to be abnormally located and aggregated in cells. This results in the apoptosis of photoreceptor cells, which cannot perform normal light signal transduction functions. Additionally, mutations in the RHO gene are associated with congenital stationary night blindness (CSNB) [2-6]. The P347S (Pro347Ser) mutation is located in the C-terminal cytoplasmic tail of the rhodopsin (RHO) protein. It may impair the polarized transport and localization of rhodopsin to rod photoreceptor outer segments, resulting in abnormal distribution of some mutant proteins and the accumulation of extracellular vesicles, ultimately leading to progressive photoreceptor degeneration. P347S is a reported pathogenic mutation associated with autosomal dominant retinitis pigmentosa (adRP) [7-9].
The huRHO-P347S mouse was generated using gene-editing technology by replacing the sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene with the corresponding human RHO gene sequence and introducing the p.P347S (CCG to TCG) point mutation into exon 5 of the human RHO gene. This model can be used to investigate the pathogenesis and progression of RHO mutation-associated autosomal dominant retinitis pigmentosa (adRP) and to evaluate potential therapeutic strategies in preclinical studies. Based on the self-developed technological innovation of TurboKnockout fusion BAC recombination, Cyagen can also provide customized services for different point mutations to meet the needs of a wide range of R&D personnel regarding the pharmacodynamics of retinitis pigmentosa (RP) and other preclinical needs.
参考文献
Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809.
Meng D, Ragi SD, Tsang SH. Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Mol Ther. 2020 Oct 7;28(10):2139-2149.
Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem. 2011 Mar 25;286(12):10551-67.
Dryja T P, Mcgee T L, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitispigmentosa[J]. Nature, 1990, 343(6256):364-366.
Zhang X, Fu W, Pang C P, et al. Screening for point mutations in rhodopsin gene among one hundred Chinese patients with retinitis pigmentosa[J]. Chinese Journal of Medical Genetics, 2002, 19(6):463-466.
Gamundi M J, Hernan I, Muntanyola M, et al. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa[J]. Human Mutation, 2008.
Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proceedings of the National Academy of Sciences. 1996;93(24):14176–14181.
Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, Cheetham ME. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018 Jan;62:1-23.
Bonilha VL, Rayborn ME, Bell BA, Marino MJ, Beight CD, Pauer GJ, Traboulsi EI, Hollyfield JG, Hagstrom SA. Retinal histopathology in eyes from patients with autosomal dominant retinitis pigmentosa caused by rhodopsin mutations. Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2161-9.
系統作製戦略
The sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene was replaced with the corresponding human RHO gene sequence, and the p.P347S (CCG to TCG) point mutation was introduced into exon 5 of the human RHO gene.

Figure 1. Diagram of the gene editing strategy for the generation of huRHO-P347S mice.
適用分野
Research on retinitis pigmentosa (RP);
Research on other retinal diseases.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
